Genes determining the course of virus persistence in the liver: Lessons from murine infection with lymphocytic choriomeningitis virus

Cellular Physiology and Biochemistry

Volumn 26, Issue 3, 2010, Pages 263-272

  Lang, Philipp A ^a   Recher, Mike ^b   Häussinger, Dieter ^c   Lang, Karl S ^c  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b Ultrasound Unit   (Switzerland)

^c HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Hepatitis; Immunopathology; Liver; Viral infection

Indexed keywords

ACTIVATION INDUCED CYTIDINE DEAMINASE; CD40 ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 7; MYELOID DIFFERENTIATION FACTOR 88; PERFORIN; PROGRAMMED DEATH 1 RECEPTOR; RETINOIC ACID INDUCIBLE PROTEIN I; SEROTONIN; STAT1 PROTEIN; T LYMPHOCYTE RECEPTOR; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CD8+ T LYMPHOCYTE; GENE MUTATION; HEPATITIS B; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INNATE IMMUNITY; LIVER; LYMPHOCYTIC CHORIOMENINGITIS; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; NONHUMAN; PERSISTENT VIRUS INFECTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; VIRUS REPLICATION;

HEPATITIS B VIRUS; HEPATITIS C VIRUS; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; MURINAE; MUS;

EID: 78650012393     PISSN: 10158987     EISSN: None     Source Type: Journal    
DOI: 10.1159/000320549     Document Type: Article

References (120)

1. Rehermann B, Nascimbeni M: Immunology of hepatitis b virus and hepatitis c virus infection. Nat Rev Immunol 2005;5:215-229.
2. Thimme R, Oldach D, Chang KM, Steiger C, Ray SC, Chisari FV: Determinants of viral clearance and persistence during acute hepatitis c virus infection. J Exp Med 2001;194:1395-1406.
3. Sobao Y, Tomiyama H, Sugi K, Tokunaga M, Ueno T, Saito S, Fujiyama S, Morimoto M, Tanaka K, Takiguchi M: The role of hepatitis b virus-specific memory cd8 t cells in the control of viral replication. J Hepatol 2002;36:105-115.
4. Rehermann B, Fowler P, Sidney J, Person J, Redeker A, Brown M, Moss B, Sette A, Chisari FV: The cytotoxic t lymphocyte response to multiple hepatitis b virus polymerase epitopes during and after acute viral hepatitis. J Exp Med 1995;181:1047-1058.
5. Ferrari C, Penna A, Bertoletti A, Valli A, Antoni AD, Giuberti T, Cavalli A, Petit MA, Fiaccadori F: Cellular immune response to hepatitis b virus-encoded antigens in acute and chronic hepatitis b virus infection. J Immunol 1990;145:3442-3449.
6. Thimme R, Wieland S, Steiger C, Ghrayeb J, Reimann KA, Purcell RH, Chisari FV: Cd8(+) t cells mediate viral clearance and disease pathogenesis during acute hepatitis b virus infection. J Virol 2003;77:68-76.
7. Urbani S, Amadei B, Tola D, Massari M, Schivazappa S, Missale G, Ferrari C: Pd-1 expression in acute hepatitis c virus (hcv) infection is associated with hcv-specific cd8 exhaustion. J Virol 2006;80:11398-11403.
8. Takeuchi O, Akira S: Innate immunity to virus infection. Immunol Rev 2009;227:75-86.
9. Pestka JM, Zeisel MB, Blaser E, Schurmann P, Bartosch B, Cosset FL, Patel AH, Meisel H, Baumert J, Viazov S, Rispeter K, Blum HE, Roggendorf M, Baumert TF: Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis c. Proc Natl Acad Sci USA 2007;104:6025-6030.
10. Buchmeier MJ, Welsh RM, Dutko FJ, Oldstone MB: The virology and immunobiology of lymphocytic chori-omeningitis virus infection. Adv Immunol 1980;30:275-331.
11. Zinkernagel RM: Lymphocytic chori-omeningitis virus and immunology. Curr Top Microbiol Immunol 2002;263:1-5.
12. Zinkernagel RM, Haenseler E, Leist T, Cerny A, Hengartner H, Althage A: T cell-mediated hepatitis in mice infected with lymphocytic choriomeningitis virus. Liver cell destruction by h-2 class i-restricted virus-specific cytotoxic t cells as a physiological correlate of the 51cr-release assay? J Exp Med 1986;164:1075-1092.
13. Zinkernagel RM, Pfau CJ, Hengartner H, Althage A: Susceptibility to murine lym-phocytic choriomeningitis maps to classimhc genes- a model for mhc/disease associations. Nature 1985;316:814-817.
14. Guidotti LG, Chisari FV: Immunobiology and pathogenesis of viral hepatitis. Annu Rev Pathol 2006;1:23-61.
15. Ahmed R, Salmi A, Butler LD, Chiller JM, Oldstone MB: Selection of genetic variants of lymphocytic choriomenin-gitis virus in spleens of persistently infected mice. Role in suppression of cy-totoxic t lymphocyte response and viral persistence. J Exp Med 1984;160:521-540.
16. Ahmed R, Oldstone MB: Organ-specific selection of viral variants during chronic infection. J Exp Med 1988;167:1719-1724.
17. Bergthaler A, Merkler D, Horvath E, Bestmann L, Pinschewer DD: Contributions of the lymphocytic choriomenin-gitis virus glycoprotein and polymerase to strain-specific differences in murine liver pathogenicity. J Gen Virol 2007;88:592-603.
18. Recher M, Lang KS, Navarini A, Hunziker L, Lang PA, Fink K, Freigang S, Georgiev P, Hangartner L, Zellweger R, Bergthaler A, Hegazy AN, Eschli B, Theocharides A, Jeker LT, Merkler D, Odermatt B, Hersberger M, Hengartner H, Zinkernagel RM: Extralymphatic virus sanctuaries as a consequence of potent t-cell activation. Nat Med 2007;13:1316-1323.
19. Jung A, Kato H, Kumagai Y, Kumar H, Kawai T, Takeuchi O, Akira S: Lymphocytoid choriomeningitis virus activates plasmacytoid dendritic cells and induces a cytotoxic t-cell response via myd88. J Virol 2008;82:196-206.
20. Horner SM, Gale M: Intracellular innate immune cascades and interferon defenses that control hepatitis c virus. J Inter-feron Cytokine Res 2009;29:489-498.
21. Wilkins C, Gale M, Jr.: Recognition of viruses by cytoplasmic sensors. Curr Opin Immunol 2010;22:41-47.
22. Lang KS, Recher M, Junt T, Navarini AA, Harris NL, Freigang S, Odermatt B, Conrad C, Ittner LM, Bauer S, Luther SA, Uematsu S, Akira S, Hengartner H, Zinkernagel RM: Toll-like receptor engagement converts t-cell autoreactivity into overt autoimmune disease. Nat Med 2005;11:138-145.
23. Zhou S, Kurt-Jones EA, Mandell L, Cerny A, Chan M, Golenbock DT, Finberg RW: Myd88 is critical for the development of innate and adaptive immunity during acute lymphocytic choriomeningitis virus infection. Eur J Immunol 2005;35:822-830.
24. Muller U, Steinhoff U, Reis LF, Hemmi S, Pavlovic J, Zinkernagel RM, Aguet M: Functional role of type i and type ii interferons in antiviral defense. Science 1994;264:1918-1921.
25. Lang PA, Cervantes-Barragan L, Verschoor A, Navarini AA, Recher M, Pellegrini M, Flatz L, Bergthaler A, Honda K, Ludewig B, Ohashi PS, Lang KS: Hematopoietic cell-derived inter-feron controls viral replication and virus-induced disease. Blood 2009;113:1045-1052.
26. Lang KS, Georgiev P, Recher M, Navarini AA, Bergthaler A, Heikenwalder M, Harris NL, Junt T, Odermatt B, Clavien PA, Pircher H, Akira S, Hengartner H, Zinkernagel RM: Immunoprivileged status of the liver is controlled by toll-like receptor 3 signaling. J Clin Invest 2006;116:2456-2463.
27. Ou R, Zhou S, Huang L, Moskophidis D: Critical role for alpha/beta and gamma interferons in persistence of lymphocytic choriomeningitis virus by clonal exhaustion of cytotoxic t cells. J Virol 2001;75:8407-8423.
28. Welzel TM, Morgan TR, Bonkovsky HL, Naishadham D, Pfeiffer RM, Wright EC, Hutchinson AA, Crenshaw AT, Bashirova A, Carrington M, Dotrang M, Sterling RK, Lindsay KL, Fontana RJ, Lee WM, Di Bisceglie AM, Ghany MG, Gretch DR, Chanock SJ, Chung RT, O'Brien TR: Variants in interferon-alpha pathway genes and response to pegylated interferon-alpha2a plus ribavirin for treatment of chronic hepatitis c virus infection in the hepatitis c antiviral long-term treatment against cirrhosis trial. Hepatology 2009;49:1847-1858.
29. Tsukada H, Ochi H, Maekawa T, Abe H, Fujimoto Y, Tsuge M, Takahashi H, Kumada H, Kamatani N, Nakamura Y, Chayama K: A polymorphism in mapkapk3 affects response to interferon therapy for chronic hepatitis c. Gastro-enterology 2009;136:1796-1805 e1796.
30. Marcello T, Grakoui A, Barba-Spaeth G, Machlin ES, Kotenko S V, MacDonald MR, Rice CM: Interferons alpha and lambda inhibit hepatitis c virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterol-ogy 2006;131:1887-1898.
31. Doyle SE, Schreckhise H, Khuu-Duong K, Henderson K, Rosler R, Storey H, Yao L, Liu H, Barahmand-pour F, Sivakumar P, Chan C, Birks C, Foster D, Clegg CH, Wietzke-Braun P, Mihm S, Klucher KM: Interleukin-29 uses a type 1 interferon-like program to promote antiviral responses in human hepatocytes. Hepatology 2006;44:896-906.
32. Liu F, Feuer R, Hassett DE, Whitton JL: Peptide vaccination of mice immune to lcmv or vaccinia virus causes serious cd8 t cell-mediated, tnf-dependent immun-opathology. J Clin Invest 2006;116:465-475.
33. Chen TY, Hsieh YS, Wu TT, Yang SF, Wu CJ, Tsay GJ, Chiou HL: Impact of serum levels and gene polymorphism of cytokines on chronic hepatitis c infection. Transl Res 2007;150:116-121.
34. Lio D, Caruso C, Di Stefano R, Colonna Romano G, Ferraro D, Scola L, Crivello A, Licata A, Valenza LM, Candore G, Craxi A, Almasio PL: Il-10 and tnf-al-pha polymorphisms and the recovery from hcv infection. Hum Immunol 2003;64:674-680.
35. Dai CY, Chuang WL, Chang WY, Chen SC, Lee LP, Hsieh MY, Hou NJ, Lin ZY, Huang JF, Wang LY, Yu ML: Tumor necrosis factor- alpha promoter polymorphism at position -308 predicts response to combination therapy in hepatitis c virus infection. J Infect Dis 2006;193:98-101.
36. Zinkernagel RM, Althage A, Cooper S, Kreeb G, Klein PA, Sefton B, Flaherty L, Stimpfling J, Shreffler D, Klein J: Ir-genes in h-2 regulate generation of anti-viral cytotoxic t cells. Mapping to k or d and dominance of unresponsiveness. J Exp Med 1978;148:592-606.
37. Doherty PC, Zinkernagel RM: T-cell-mediated immunopathology in viral infections. Transplant Rev 1974;19:89-120.
38. Zinkernagel RM, Doherty PC: Restriction of in vitro t cell-mediated cytotox-icity in lymphocytic choriomeningitis within a syngeneic or semiallogeneic system. Nature 1974;248:701-702.
39. Chuang WC, Sarkodie F, Brown CJ, Owusu-Ofori S, Brown J, Li C, Navarrete C, Klenerman P, Allain JP: Protective effect of hla-b57 on hcv genotype 2 infection in a west african population. J Med Virol 2007;79:724-733.
40. McKiernan SM, Hagan R, Curry M, McDonald GS, Kelly A, Nolan N, Walsh A, Hegarty J, Lawlor E, Kelleher D: Distinct mhc class i and ii alleles are associated with hepatitis c viral clearance, originating from a single source. Hepatology 2004;40:108-114.
41. Neumann-Haefelin C, McKiernan S, Ward S, Viazov S, Spangenberg HC, Killinger T, Baumert TF, Nazarova N, Sheridan I, Pybus O, von Weizsacker F, Roggendorf M, Kelleher D, Klenerman P, Blum HE, Thimme R: Dominant influence of an hla-b27 restricted cd8+ t cell response in mediating hcv clearance and evolution. Hepatology 2006;43:563-572.
42. Neumann-Haefelin C, Thimme R: Impact of the genetic restriction of virus-specific t-cell responses in hepatitis c virus infection. Genes Immun 2007;8:181-192.
43. Thio CL, Gao X, Goedert JJ, Vlahov D, Nelson KE, Hilgartner MW, O'Brien SJ, Karacki P, Astemborski J, Carrington M, Thomas DL: Hla-cw*04 and hepatitis c virus persistence. J Virol 2002;76:4792-4797.
44. Blattman JN, Grayson JM, Wherry EJ, Kaech SM, Smith KA, Ahmed R: Therapeutic use of il-2 to enhance antiviral t-cell responses in vivo. Nat Med 2003;9:540-547.
45. Kasaian MT, Biron CA: Effects of cyclosporin a on il-2 production and lymphocyte proliferation during infection of mice with lymphocytic chori-omeningitis virus. J Immunol 1990;144:299-306.
46. Semmo N, Day CL, Ward SM, Lucas M, Harcourt G, Loughry A, Klenerman P: Preferential loss of il-2-secreting cd4+ thelper cells in chronic hcv infection. Hepatology 2005;41:1019-1028.
47. Lang KS, Recher M, Navarini AA, Harris NL, Lohning M, Junt T, Probst HC, Hengartner H, Zinkernagel RM: Inverse correlation between il-7 receptor expression and cd8 t cell exhaustion during persistent antigen stimulation. Eur J Immunol 2005;35:738-745.
48. Wherry EJ, Barber DL, Kaech SM, Blattman JN, Ahmed R: Antigen-independent memory cd8 t cells do not develop during chronic viral infection. Proc Natl Acad Sci USA 2004;101:16004-16009.
49. Pellegrini M, Calzascia T, Elford AR, Shahinian A, Lin AE, Dissanayake D, Dhanji S, Nguyen LT, Gronski MA, Morre M, Assouline B, Lahl K, Sparwasser T, Ohashi PS, Mak TW: Adjuvant il-7 antagonizes multiple cellular and molecular inhibitory networks to enhance immunotherapies. Nat Med 2009;15:528-536.
50. Golden-Mason L, Burton JR, Jr., Castelblanco N, Klarquist J, Benlloch S, Wang C, Rosen HR: Loss of il-7 receptor alpha-chain (cd127) expression in acute hcv infection associated with viral persistence. Hepatology 2006;44:1098-1109.
51. Radziewicz H, Ibegbu CC, Fernandez ML, Workowski KA, Obideen K, Wehbi M, Hanson HL, Steinberg JP, Masopust D, Wherry EJ, Altman JD, Rouse BT, Freeman GJ, Ahmed R, Grakoui A: Liver-infiltrating lymphocytes in chronic human hepatitis c virus infection display an exhausted phenotype with high levels of pd-1 and low levels of cd127 expression. J Virol 2007;81:2545-2553.
52. Bengsch B, Spangenberg HC, Kersting N, Neumann-Haefelin C, Panther E, von Weizsacker F, Blum HE, Pircher H, Thimme R: Analysis of cd127 and klrg1 expression on hepatitis c virus-specific cd8+ t cells reveals the existence of different memory t-cell subsets in the peripheral blood and liver. J Virol 2007;81:945-953.
53. Barber DL, Wherry EJ, Masopust D, Zhu B, Allison JP, Sharpe AH, Freeman GJ, Ahmed R: Restoring function in exhausted cd8 t cells during chronic viral infection. Nature 2006;439:682-687.
54. Ha SJ, Mueller SN, Wherry EJ, Barber DL, Aubert RD, Sharpe AH, Freeman GJ, Ahmed R: Enhancing therapeutic vaccination by blocking pd-1-mediated inhibitory signals during chronic infection. J Exp Med 2008;205:543-555.
55. Penna A, Pilli M, Zerbini A, Orlandini A, Mezzadri S, Sacchelli L, Missale G, Ferrari C: Dysfunction and functional restoration of hcv-specific cd8 responses in chronic hepatitis c virus infection. Hepatology 2007;45:588-601.
56. Kolumam GA, Thomas S, Thompson LJ, Sprent J, Murali-Krishna K: Type i interferons act directly on cd8 t cells to allow clonal expansion and memory formation in response to viral infection. J Exp Med 2005;202:637-650.
57. Aichele P, Unsoeld H, Koschella M, Schweier O, Kalinke U, Vucikuja S: Cd8 t cells specific for lymphocytic chori-omeningitis virus require type i ifn receptor for clonal expansion. J Immunol 2006;176:4525-4529.
58. Brooks DG, Trifilo MJ, Edelmann KH, Teyton L, McGavern DB, Oldstone MB: Interleukin-10 determines viral clearance or persistence in vivo. Nat Med 2006;12:1301-1309.
59. Ejrnaes M, Filippi CM, Martinic MM, Ling EM, Togher LM, Crotty S, von Herrath MG: Resolution of a chronic viral infection after interleukin-10 receptor blockade. J Exp Med 2006;203:2461-2472.
60. Yee LJ, Tang J, Gibson AW, Kimberly R, Van Leeuwen DJ, Kaslow RA: Interleukin 10 polymorphisms as predictors of sustained response in antiviral therapy for chronic hepatitis c infection. Hepatology 2001;33:708-712.
61. Knapp S, Hennig BJ, Frodsham AJ, Zhang L, Hellier S, Wright M, Goldin R, Hill AV, Thomas HC, Thursz MR: Interleukin-10 promoter polymorphisms and the outcome of hepatitis c virus infection. Immunogenetics 2003;55:362-369.
62. Mangia A, Santoro R, Piattelli M, Pazienza V, Grifa G, Iacobellis A, Andriulli A: Il-10 haplotypes as possible predictors of spontaneous clearance of hcv infection. Cytokine 2004;25:103-109.
63. Oleksyk TK, Thio CL, Truelove AL, Goedert JJ, Donfield SM, Kirk GD, Thomas DL, O'Brien SJ, Smith MW: Single nucleotide polymorphisms and haplotypes in the il10 region associated with hcv clearance. Genes Immun 2005;6:347-357.
64. Guidotti LG, Borrow P, Brown A, McClary H, Koch R, Chisari FV: Noncytopathic clearance of lymphocytic choriomenin-gitis virus from the hepatocyte. J Exp Med 1999;189:1555-1564.
65. Dai CY, Chuang WL, Chang WY, Chen SC, Lee LP, Hsieh MY, Hou NJ, Lin Z Y, Wang LY, Yu ML: Polymorphisms in the interferon-gamma gene at position +874 in patients with chronic hepatitis c treated with high-dose interferon-alpha and ribavirin. Antiviral Res 2005;67:93-97.
66. Kagi D, Ledermann B, Burki K, Seiler P, Odermatt B, Olsen KJ, Podack ER, Zinkernagel RM, Hengartner H: Cyto-toxicity mediated by t cells and natural killer cells is greatly impaired in perforin-deficient mice. Nature 1994;369:31-37.
67. Planz O, Ehl S, Furrer E, Horvath E, Brundler MA, Hengartner H, Zinkernagel RM: A critical role for neutralizing-anti-body-producing b cells, cd4(+) t cells, and interferons in persistent and acute infections of mice with lymphocytic chori-omeningitis virus: Implications for adoptive immunotherapy of virus carriers. Proc Natl Acad Sci USA 1997;94:6874-6879.
68. Battegay M, Moskophidis D, Rahemtulla A, Hengartner H, Mak TW, Zinkernagel RM: Enhanced establishment of a virus carrier state in adult cd4+ t-cell-deficient mice. J Virol 1994;68:4700-4704.
69. Battegay M, Bachmann MF, Burhkart C, Viville S, Benoist C, Mathis D, Hengartner H, Zinkernagel RM: Antiviral immune responses of mice lacking mhc class ii or its associated invariant chain. Cell Immunol 1996;167:115-121.
70. Recher M, Lang KS, Hunziker L, Freigang S, Eschli B, Harris NL, Navarini A, Senn BM, Fink K, Lotscher M, Hangartner L, Zellweger R, Hersberger M, Theocharides A, Hengartner H, Zinkernagel RM: Deliberate removal of t cell help improves virus-neutralizing antibody production. Nat Immunol 2004;5:934-942.
71. Brundler MA, Aichele P, Bachmann M, Kitamura D, Rajewsky K, Zinkernagel RM: Immunity to viruses in b cell-deficient mice: Influence of antibodies on virus persistence and on t cell memory. Eur J Immunol 1996;26:2257-2262.
72. Chapel HM, Christie JM, Peach V, Chapman RW: Five-year follow-up of patients with primary antibody deficiencies following an outbreak of acute hepatitis c. Clin Immunol 2001;99:320-324.
73. Christie JM, Healey CJ, Watson J, Wong VS, Duddridge M, Snowden N, Rosenberg WM, Fleming KA, Chapel H, Chapman RW: Clinical outcome of hypogammaglobulinaemic patients following outbreak of acute hepatitis c: 2 year follow up. Clin Exp Immunol 1997;110:4-8.
74. Yu MY, Bartosch B, Zhang P, Guo ZP, Renzi PM, Shen LM, Granier C, Feinstone SM, Cosset FL, Purcell RH: Neutralizing antibodies to hepatitis c virus (hcv) in immune globulins derived from anti-hcv-positive plasma. Proc Natl Acad Sci USA 2004;101:7705-7710.
75. Borrow P, Tishon A, Lee S, Xu J, Grewal IS, Oldstone MB, Flavell RA: Cd40l-de-ficient mice show deficits in antiviral immunity and have an impaired memory cd8+ ctl response. J Exp Med 1996;183:2129-2142.
76. Lang PA, Contaldo C, Georgiev P, El-Badry AM, Recher M, Kurrer M, Cer-vantes-Barragan L, Ludewig B, Calzascia T, Bolinger B, Merkler D, Odermatt B, Bader M, Graf R, Clavien PA, Hegazy AN, Lohning M, Harris NL, Ohashi PS, Hengartner H, Zinkernagel RM, Lang KS: Aggravation of viral hepatitis by platelet-derived serotonin. Nat Med 2008;14:756-761.
77. Guidotti LG, McClary H, Loudis JM, Chisari FV: Nitric oxide inhibits hepatitis b virus replication in the livers of transgenic mice. J Exp Med 2000;191:1247-1252. (Pubitemid 30207687)
78. Areschoug T, Gordon S: Pattern recognition receptors and their role in innate immunity: Focus on microbial protein ligands. Contrib Microbiol 2008;15:45-60.
79. Areschoug T, Gordon S: Scavenger receptors: Role in innate immunity and microbial pathogenesis. Cell Microbiol 2009;11:1160-1169.
80. Kepler TB, Chan C: Spatiotemporal programming of a simple inflammatory process. Immunol Rev 2007;216:153-163.
81. Martinon F, Tschopp J: Nlrs join tlrs as innate sensors of pathogens. Trends Immunol 2005;26:447-454.
82. Bowie A G, Unterholzner L: Viral evasion and subversion of pattern-recognition receptor signalling. Nat Rev Immunol 2008;8:911-922.
83. Meylan E, Curran J, Hofmann K, Moradpour D, Binder M, Bartenschlager R, Tschopp J: Cardif is an adaptor protein in the rig-i antiviral pathway and is targeted by hepatitis c virus. Nature 2005;437:1167-1172.
84. Fortunato G, Calcagno G, Bresciamorra V, Salvatore E, Filla A, Capone S, Liguori R, Borelli S, Gentile I, Borrelli F, Borgia G, Sacchetti L: Multiple sclerosis and hepatitis c virus infection are associated with single nucleotide polymorphisms in interferon pathway genes. J Interferon Cytokine Res 2008;28:141-152.
85. Zhang SY, Boisson-Dupuis S, Chapgier A, Yang K, Bustamante J, Puel A, Picard C, Abel L, Jouanguy E, Casanova JL: Inborn errors of interferon (ifn)-mediated immunity in humans: Insights into the respective roles of ifn-alpha/beta, ifn-gamma, and ifn-lambda in host defense. Immunol Rev 2008;226:29-40.
86. Dupuis S, Jouanguy E, Al-Hajjar S, Fieschi C, Al-Mohsen IZ, Al-Jumaah S, Yang K, Chapgier A, Eidenschenk C, Eid P, Al Ghonaium A, Tufenkeji H, Frayha H, Al-Gazlan S, Al-Rayes H, Schreiber RD, Gresser I, Casanova JL: Impaired response to interferon-alpha/beta and lethal viral disease in human stat1 deficiency. Nat Genet 2003;33:388-391.
87. Kotenko SV, Gallagher G, Baurin VV, Lewis-Antes A, Shen M, Shah NK, Langer JA, Sheikh F, Dickensheets H, Donnelly RP: Ifn-lambdas mediate antiviral protection through a distinct class ii cytokine receptor complex. Nat Immunol 2003;4:69-77.
88. Sheppard P, Kindsvogel W, Xu W, Henderson K, Schlutsmeyer S, Whitmore TE, Kuestner R, Garrigues U, Birks C, Roraback J, Ostrander C, Dong D, Shin J, Presnell S, Fox B, Haldeman B, Cooper E, Taft D, Gilbert T, Grant FJ, Tackett M, Krivan W, McKnight G, Clegg C, Foster D, Klucher KM: Il-28, il-29 and their class ii cytokine receptor il-28r. Nat Immunol 2003;4:63-68.
89. Thio CL, Thomas DL: Interleukin-28b: A key piece of the hepatitis c virus recovery puzzle. Gastroenterology 2010;138:1240-1243.
90. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O'Huigin C, Kidd J, Kidd K, Khakoo SI, Alexander G, Goedert JJ, Kirk GD, Donfield SM, Rosen HR, Tobler LH, Busch MP, McHutchison JG, Goldstein DB, Carrington M: Genetic variation in il28b and spontaneous clearance of hepatitis c virus. Nature 2009;461:798-801.
91. Ank N, West H, Bartholdy C, Eriksson K, Thomsen AR, Paludan SR: Lambda interferon (ifn-lambda), a type iii ifn, is induced by viruses and ifns and displays potent antiviral activity against select virus infections in vivo. J Virol 2006;80:4501-4509.
92. Kundig TM, Schorle H, Bachmann MF, Hengartner H, Zinkernagel RM, Horak I: Immune responses in interleukin-2-deficient mice. Science 1993;262:1059-1061.
93. Mazzucchelli R, Durum SK: Interleukin-7 receptor expression: Intelligent design. Nat Rev Immunol 2007;7:144-154.
94. Boettler T, Panther E, Bengsch B, Nazarova N, Spangenberg HC, Blum HE, Thimme R: Expression of the interleukin-7 receptor alpha chain (cd127) on virus-specific cd8+ t cells identifies functionally and phenotypically defined memory t cells during acute resolving hepatitis b virus infection. J Virol 2006;80:3532-3540.
95. Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu YJ, Pulendran B, Palucka K: Immunobiology of dendritic cells. Annu Rev Immunol 2000;18:767-811.
96. Nishimura H, Nose M, Hiai H, Minato N, Honjo T: Development of lupus-like autoimmune diseases by disruption of the pd-1 gene encoding an itim motif-carrying immunoreceptor. Immunity 1999;11:141-151.
97. Rodig N, Ryan T, Allen JA, Pang H, Grabie N, Chernova T, Greenfield EA, Liang SC, Sharpe AH, Lichtman AH, Freeman GJ: Endothelial expression of pd-l1 and pd-l2 down-regulates cd8+ t cell activation and cytolysis. Eur J Immunol 2003;33:3117-3126.
98. Frohlich A, Kisielow J, Schmitz I, Freigang S, Shamshiev AT, Weber J, Marsland BJ, Oxenius A, Kopf M: Il-21r on t cells is critical for sustained functionality and control of chronic viral infection. Science 2009;324:1576-1580.
99. Elsaesser H, Sauer K, Brooks DG: Il-21 is required to control chronic viral infection. Science 2009;324:1569-1572.
100. Holm C, Nyvold CG, Paludan SR, Thomsen AR, Hokland M: Interleukin-21 mrna expression during virus infections. Cytokine 2006;33:41-45.
101. Zou M, Li MM, Huang SB, Li XJ, Zhou YP, Liu SW: [the detection of anti-nuclear antibody and il-21 in patients infected with hepatitis c virus.]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 2010;26:471-472.
102. Ochsenbein AF, Riddell SR, Brown M, Corey L, Baerlocher GM, Lansdorp PM, Greenberg PD: Cd27 expression promotes long-term survival of functional effector-memory cd8+ cytotoxic t lymphocytes in hiv-infected patients. J Exp Med 2004;200:1407-1417.
103. Jagannathan P, Osborne CM, Royce C, Manion MM, Tilton JC, Li L, Fischer S, Hallahan CW, Metcalf JA, McLaughlin M, Pipeling M, McDyer JF, Manley TJ, Meier JL, Altman JD, Hertel L, Davey RT, Jr., Connors M, Migueles SA: Comparisons of cd8+ t cells specific for human immunodeficiency virus, hepatitis c virus, and cytomegalovirus reveal differences in frequency, immunodominance, phenotype, and interleukin-2 responsiveness. J Virol 2009;83:2728-2742.
104. Matter M, Odermatt B, Yagita H, Nuoffer JM, Ochsenbein AF: Elimination of chronic viral infection by blocking cd27 signaling. J Exp Med 2006;203:2145-2155.
105. Matter M, Mumprecht S, Pinschewer DD, Pavelic V, Yagita H, Krautwald S, Borst J, Ochsenbein AF: Virus-induced polyclonal b cell activation improves protective ctl memory via retained cd27 expression on memory ctl. Eur J Immunol 2005;35:3229-3239.
106. Kamanaka Y, Kawabata A, Matsuya H, Taga C, Sekiguchi F, Kawao N: Effect of a potent inos inhibitor (ono-1714) on acetaminophen-induced hepatotoxicity in the rat. Life Sci 2003;74:793-802.
107. Kurabayashi M, Takeyoshi I, Yoshinari D, Koibuchi Y, Ohki T, Matsumoto K, Morishita Y: No donor ameliorates ischemia-reperfusion injury of the rat liver with inos attenuation. J Invest Surg 2005;18:193-200. (Pubitemid 41200611)
108. Venkatraman A, Shiva S, Wigley A, Ulasova E, Chhieng D, Bailey SM, Darley-Usmar VM: The role of inos in alcohol-dependent hepatotoxicity and mitochondrial dysfunction in mice. Hepatology 2004;40:565-573.
109. Gorg B, Qvartskhava N, Voss P, Grune T, Haussinger D, Schliess F: Reversible inhibition of mammalian glutamine syn-thetase by tyrosine nitration. FEBS Lett 2007;581:84-90.
110. Gorg B, Wettstein M, Metzger S, Schliess F, Haussinger D: Lps-induced tyrosine nitration of hepatic glutamine syn-thetase. Hepatology 2005;42:499. (Pubitemid 41061108)
111. Reinehr R, Gorg B, Hongen A, Haussinger D: Cd95-tyrosine nitration inhibits hyperosmotic and cd95 ligand-induced cd95 activation in rat hepatocytes. J Biol Chem 2004;279:10364-10373.
112. Reinehr R, Haussinger D: Hyperosmotic activation of the cd95 death receptor system. Acta Physiol (Oxf) 2006;187:199-203.
113. Bao X, Cui J, Wu Y, Han X, Gao C, Hua Z, Shen P: The roles of endogenous reactive oxygen species and nitric oxide in triptolide-induced apoptotic cell death in macrophages. J Mol Med 2007;85:85-98.
114. Dimmeler S, Haendeler J, Nehls M, Zeiher AM: Suppression of apoptosis by nitric oxide via inhibition of interleukin-1beta-converting enzyme (ice)-like and cysteine protease protein (cpp)-32-like proteases. J Exp Med 1997;185:601-607.
115. Dimmeler S, Zeiher AM: Nitric oxide-an endothelial cell survival factor. Cell Death Differ 1999;6:964-968.
116. Haendeler J, Zeiher AM, Dimmeler S: Nitric oxide and apoptosis. Vitam Horm 1999;57:49-77.
117. Taylor EL, Megson IL, Haslett C, Rossi AG: Nitric oxide: A key regulator of myeloid inflammatory cell apoptosis. Cell Death Differ 2003;10:418-430.
118. Koeppel TA, Mihaljevic N, Kraenzlin B, Loehr M, Jesenofsky R, Post S, Palma P: Enhanced inos gene expression in the steatotic rat liver after normothermic ischemia. Eur Surg Res 2007;39:303-311.
119. Whittle BJ, Morschl E, Pozsar J, Moran AP, Laszlo F: Helicobacter pylori li-popolysaccharide provokes inos-medi-ated acute systemic microvascular inflammatory responses in rat cardiac, hepatic, renal and pulmonary tissues. J Physiol Paris 2001;95:257-259.
120. Feld JJ, Hoofnagle JH: Mechanism of action of interferon and ribavirin in treatment of hepatitis c. Nature 2005;436:967-972.